ABSTRACT
Liquid biopsy represents a paradigm (A major change in thinking or approach) shift in modern oncology and non-invasive diagnostics. Unlike traditional tissue biopsies, which require invasive surgical procedures to obtain a physical sample of a tumour, liquid biopsy analyses biological markers, primarily circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs), shed into bodily fluids like blood. Liquid biopsy has gained importance in early diagnosis, treatment selection, and monitoring therapeutic response. Its growing role in precision medicine makes it a promising tool for personalised healthcare. This article explores the scientific mechanisms, clinical procedures, and diagnostic interpretations of the test.
INTRODUCTION
Tissue biopsy has been regarded as the gold standard for cancer diagnosis and characterisation for many decades. In recent years, liquid biopsy has emerged as a revolutionary advancement in oncological diagnostics. This minimally invasive technique, typically performed using a blood sample, enables the detection of circulating tumour components such as tumour DNA, RNA, and cancer cells present in the bloodstream. For years, understanding the internal state of a tumour required invasive surgical procedures to extract tissue. While effective, these "solid" biopsies are often painful and can only capture a localised snapshot of a disease. Liquid biopsy changes this dynamic by utilising the body's natural circulatory system. It operates on the premise that cells—especially those related to disease—shed fragments of their genetic material into bodily fluids. This allows healthcare providers to monitor health in real-time, offering a dynamic and holistic view of a patient’s condition without the need for surgery.
SCIENTIFIC PRINCIPLE BEHIND THE LIQUID BIOPSY
The test is rooted in the biological process of cellular turnover. All cells in the body follow a cycle of growth and death. When cells undergo apoptosis (programmed cell death) or necrosis (uncontrolled cell death), they rupture and release their contents. In a healthy individual, this debris is efficiently cleared. However, in various health conditions, particularly cancer, these fragments enter the bloodstream in detectable quantities.
The liquid biopsy specifically targets cell-free DNA (cfDNA). Because diseased cells carry distinct genetic mutations, their DNA fragments act as unique molecular signatures. Advanced sequencing technology can distinguish these abnormal signatures from the healthy DNA that naturally circulates in the plasma.
KEY COMPONENTS OF THE TEST
A liquid biopsy screens for several critical markers that provide a multi-dimensional view of a disease:
- Circulating Tumour DNA (ctDNA): Genetic fragments originating directly from a tumour.
- Circulating Tumour Cells (CTCs): Intact cells that have broken away from a primary site and are travelling through the vascular system.
- Exosomes: Tiny extracellular vesicles that carry proteins and RNA, serving as a communication bridge between cells.
- Circulating RNA (cfRNA): Fragments of RNA that provide insight into gene expression and cellular activity.
WHAT IS THE PROCEDURE?
The procedure is remarkably straightforward and mirrors a routine medical check-up:
- Sample Collection: A small amount of blood (typically 7–10 mL) is drawn from a vein.
- Stabilisation: The sample is placed in specialised tubes to prevent the degradation of fragile genetic material.
- Separation: In a laboratory, the blood is spun in a centrifuge to separate the plasma, which contains the circulating DNA and cells.
- Molecular Analysis: Scientists use high-sensitivity techniques like Next-Generation Sequencing (NGS) to scan millions of DNA fragments for specific mutations or abnormalities.
INTERPRETATION OF THE TEST
Interpreting a liquid biopsy involves measuring the concentration and type of genetic markers found:
- Detection of Mutations: Identifying specific genetic errors helps doctors choose targeted therapies that are more likely to be effective for that individual.
- Quantitative Tracking: A decrease in the level of circulating markers after starting treatment indicates a positive response. Conversely, a rising trend may suggest that the disease is progressing or becoming resistant to current medication.
- Minimal Residual Disease (MRD): Post-surgery, the test can detect "invisible" traces of disease that may not be seen on traditional imaging, helping to determine if additional preventative treatment is needed.
HEALTH ISSUES WHERE LIQUID BIOPSY IS ADVISED
While predominantly used in oncology, liquid biopsy is becoming relevant for several health scenarios:
- Cancer Management: Particularly for lung, breast, colorectal, and prostate cancers.
- Treatment Resistance: Detecting when a disease has evolved to bypass current drugs.
- Early Screening: Investigating suspicious findings when a surgical biopsy is too risky.
- Prenatal Testing: Non-invasive prenatal screening (NIPS) uses similar technology to check the health of a fetus through the mother's blood.
FACTORS AFFECTING THE RESULTS
The accuracy of a liquid biopsy can be influenced by several biological and technical factors:
- Shedding Rate: Not all diseased areas release genetic material at the same rate; some "quiet" tumours may be harder to detect.
- Inflammation and Trauma: Physical stress or recent surgery can increase the amount of healthy cell-free DNA in the blood, which may temporarily mask diseased markers.
- Ageing: Natural age-related genetic changes in blood cells can sometimes mimic disease-related mutations.
ADVANTAGES OF THE TEST
- Safety and Comfort: It eliminates the risks associated with invasive surgery, such as infection or bleeding.
- Comprehensive Insight: It captures the genetic profile of the entire body’s disease burden, rather than just one small area.
- Real-Time Monitoring: Since it is easy to repeat, it allows for frequent "snapshots" of how a patient is responding to treatment.
- Early Detection: It can often pick up molecular changes months before they are visible on a CT scan or MRI.
AYURVEDA INSIGHT
Ayurveda has long recognised that the fluids of the body are the carriers of vital information and health. The concept of Rasa Dhatu (the primary nutritional fluid or plasma) aligns closely with the modern understanding of liquid biopsy.
In Ayurvedic physiology, Rasa (the primary nutritional fluid or plasma) is the first tissue formed after digestion and circulates throughout the body to nourish all other tissues (Dhatus). It is considered a reflection of the body’s overall equilibrium. Imbalances or toxins (Ama) are thought to manifest first in the Rasa (the primary nutritional fluid or plasma) Dhatu (Tissues) before they manifest as physical symptoms in solid organs. The liquid biopsy is, in essence, a modern scientific validation of this ancient principle: that by studying the quality and contents of our "internal waters," we can understand the health of the entire biological system.
AYURVEDIC HERBS FOR HEALTH ISSUES IN WHICH LIQUID BIOPSY IS ADVISED
Kanchnaar (Bauhinia variegata)
In Ayurveda, Kanchnaar is described as a powerful herb for reducing Granthi and Arbuda (abnormal swellings and glandular enlargements) by balancing Kapha and Meda dosha. It supports lymphatic drainage and helps clear accumulated toxins from deeper tissues. Classical formulations like Kanchnaar Guggul are traditionally used for glandular disorders and abnormal tissue growth. From a modern perspective, the bark contains bioactive compounds such as flavonoids, quercetin, and kaempferol, which exhibit antioxidant and antiproliferative activities. These compounds help regulate cellular growth pathways and reduce oxidative stress linked with tumour progression. Research also suggests immunomodulatory effects that may support cellular regulation and tissue normalisation.
Guggul (Commiphora wightii)
Guggul is highly valued in Ayurveda for removing Ama (metabolic toxins) and balancing aggravated Vata, Pitta and Kapha doshas associated with chronic inflammatory masses. It improves circulation, promotes detoxification, and supports proper metabolism of tissues (Dhatu Agni). Ayurveda considers it useful in resolving hard swellings and maintaining healthy channels (Srotoshodhana). Modern studies identify guggulsterones (E- and Z-guggulsterone) as the primary active constituents. These compounds demonstrate anti-inflammatory and apoptosis-inducing properties by modulating NF-κB signalling pathways. They may help regulate abnormal cell proliferation and reduce inflammatory mediators contributing to disease progression.
Shallaki (Boswellia serrata)
In Ayurvedic texts, Shallaki is known for pacifying Vata and Kapha and relieving Shotha (inflammation) and pain associated with chronic disorders. It supports tissue healing and helps maintain joint and soft tissue integrity. Ayurveda emphasises its role in reducing inflammatory swelling and improving circulation in affected tissues. Modern pharmacology attributes its effects mainly to boswellic acids, especially AKBA (Acetyl-11-keto-β-boswellic acid). These compounds inhibit the 5-lipoxygenase pathway, thereby reducing leukotriene-mediated inflammation. Studies also indicate potential anti-tumour and anti-angiogenic properties, helping limit abnormal tissue expansion.
Tulsi (Ocimum sanctum)
Tulsi is regarded in Ayurveda as a sacred Rasayana that enhances Ojas (Vital Essence) and strengthens immunity. It supports detoxification and protects the body against environmental and internal stressors. Traditionally, it is used to maintain respiratory and systemic health while preventing disease progression. Modern research highlights active constituents such as eugenol, ursolic acid, and rosmarinic acid, which possess antioxidant and anti-inflammatory effects. These compounds help neutralise free radicals, regulate inflammatory cytokines, and support immune surveillance mechanisms. Tulsi also demonstrates adaptogenic properties that assist the body in maintaining cellular balance.
Giloy (Tinospora cordifolia)
In Ayurveda, Giloy is classified as a potent Rasayana known for enhancing immunity and correcting Tridosha (all three dosha) imbalance. It is widely used in chronic disorders where immune dysfunction and toxin accumulation play a role. Giloy improves digestion, metabolism, and the resilience of body tissues while promoting natural detoxification. From a modern scientific perspective, key phytochemicals include tinosporaside, cordifolioside, and berberine-like alkaloids. These compounds exhibit immunomodulatory and antioxidant actions that help regulate inflammatory responses. Studies suggest Giloy supports macrophage activation and cellular defence mechanisms important in disease control.
Ashwagandha (Withania somnifera)
Ashwagandha is a renowned Ayurvedic Rasayana used to restore strength, improve vitality, and counter Dhatu Kshaya (tissue depletion). It enhances adaptability during chronic illness and stress-related conditions. Ayurveda recognises its role in rejuvenation and maintaining systemic stability. Modern science attributes its therapeutic actions primarily to withanolides, particularly withaferin A, which show anti-inflammatory and anti-proliferative activities. These compounds help induce programmed cell death in abnormal cells and reduce oxidative damage. Ashwagandha also supports neuroendocrine balance, improving overall resilience during long-term disease management.
CONCLUSION
Liquid biopsy stands as a transformative milestone in modern diagnostics, moving us toward a future where healthcare is both proactive and personalised. By reading the molecular signals circulating within the blood, medical professionals can detect underlying issues earlier, tailor treatments with higher precision, and monitor recovery with minimal physical burden on the patient. This technology effectively bridges the gap between complex molecular biology and the holistic principle that our internal fluids hold the key to our overall well-being. Ultimately, it offers a gentler, more intelligent path to maintaining health and managing disease.
No comments:
Post a Comment